Studies

Retatrutide Cardiovascular Outcomes: What Phase 3 Shows

Comprehensive analysis of Phase 3 trial data examining retatrutide's cardiovascular effects, safety profile, and implications for metabolic disease treatment in research settings.

Retatrutide and Insulin Sensitivity: Metabolic Improvements Beyond Weight

Research analysis of retatrutide's direct effects on insulin sensitivity, glucose metabolism, and metabolic health independent of weight loss mechanisms.

Retatrutide Phase 2b Full Data: NCT04881383 Results Breakdown

Comprehensive analysis of the retatrutide Phase 2b clinical trial (NCT04881383), examining weight loss efficacy, metabolic outcomes, safety profile, and dose-response relationships in obese participants.

Tirzepatide Weight Regain After Stopping: What the Data Shows

A comprehensive analysis of weight regain patterns following tirzepatide discontinuation, examining clinical trial data, physiological mechanisms, and strategies for weight maintenance.

Tirzepatide Body Composition: Fat vs Muscle Loss Data

Analysis of clinical data on tirzepatide's effects on body composition, including fat mass reduction, lean mass preservation, and muscle loss concerns.

SURMOUNT-1 Trial Results: What 22.5% Weight Loss Actually Means

A comprehensive analysis of the SURMOUNT-1 trial examining tirzepatide's unprecedented 22.5% weight loss results, methodology, clinical implications, and what these findings mean for obesity research.

Tirzepatide Weight Loss by Week: SURMOUNT-1 Trajectory Data Analysis

Comprehensive analysis of week-by-week weight loss trajectories from the SURMOUNT-1 trial, examining tirzepatide's dose-dependent effects and temporal patterns across 72 weeks of treatment.

Sikiric et al: 30 Years of BPC-157 Research Summarized

A comprehensive overview of three decades of BPC-157 research led by Professor Predrag Sikiric's team, examining the evolution of findings from gastric protection to systemic healing mechanisms.

BPC-157 and the Nitric Oxide Pathway: Mechanistic Insights into Enhanced Healing

An in-depth examination of how BPC-157 modulates nitric oxide signaling to promote tissue repair, angiogenesis, and cytoprotection across multiple organ systems

BPC-157 and Angiogenesis: VEGF Pathway Research

Comprehensive examination of BPC-157's mechanisms in promoting angiogenesis through VEGF pathway modulation, including molecular signaling, receptor interactions, and therapeutic implications.

BPC-157 Neuroprotection in Traumatic Brain Injury: A Comprehensive Research Analysis

An in-depth examination of BPC-157's neuroprotective mechanisms in traumatic brain injury models, exploring molecular pathways, blood-brain barrier protection, and therapeutic implications for TBI research.

BPC-157 for Muscle Tear Recovery: Animal Model Evidence

A comprehensive examination of preclinical research demonstrating BPC-157's potential in accelerating muscle tear healing, including mechanisms of action and experimental protocols from animal studies.

BPC-157 for Gut Healing and IBD: Mechanism and Evidence

Comprehensive analysis of BPC-157's gastroprotective mechanisms, its effects on inflammatory bowel disease models, and the current state of research evidence for intestinal healing applications.

BPC-157 for Tendon Repair: What the Research Actually Shows

A comprehensive analysis of BPC-157's effects on tendon healing based on published research, examining mechanisms, protocols, and limitations of current evidence.

Retatrutide 2-Year Data: Why There Is No Weight Loss Plateau

Analysis of landmark 2-year retatrutide trial data revealing continuous weight loss without plateau, examining the mechanisms behind GIP/GLP-1/glucagon tri-agonism and implications for obesity treatment.

Retatrutide for BMI 35+: 30% Body Weight Loss Data

Comprehensive analysis of retatrutide clinical trial data demonstrating up to 30% body weight reduction in participants with BMI ≥35, examining mechanisms, efficacy, and metabolic outcomes.

Retatrutide for Fatty Liver Disease: 86% Clearance Data Analysis

Comprehensive analysis of Phase 2 clinical data demonstrating retatrutide's remarkable 86% hepatic steatosis resolution rate in NAFLD/MASH patients, examining mechanisms and implications.

Retatrutide Ketone Body Response and Metabolic Switch: Comprehensive Analysis

Detailed examination of retatrutide's effects on ketone body production, metabolic switching mechanisms, and implications for fat oxidation research.

Retatrutide Phase 3 Results: 25% Weight Loss Without Plateau at 2 Years

Analysis of retatrutide's Phase 3 trial data showing sustained 25% weight loss at 2 years without plateau effect in obesity treatment research.